Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Drug News Perspect. 2009 Jul-Aug;22(6):319-24. doi: 10.1358/dnp.2009.22.6.1395255.

Neuropeptides: relevance in treatment of depression and anxiety disorders.

Author information

  • 1Child and Adolescent Psychopharmacology, Creighton University Medical Center, Omaha, Nebraska 68131, USA. VishalMadaan@creighton.edu

Abstract

The etiology and pathophysiology of both depression and anxiety remain unclear, but involve dysfunctional monoaminergic neurotransmission and function. The currently available antidepressant medications that work through optimizing the monoaminergic system are often limited by their lack of efficacy or their adverse effects. There is increasing evidence that some neuropeptides, including substance P, corticotropin-releasing factor, neuropeptide Y, vasopressin and galanin, may have relevance in both depression and anxiety. Integration of anatomical, physiological and clinical evidence suggests that modulation of monoaminergic transmission is the most likely mechanism by which neuropeptides may work in these disorders. These neuropeptides and their receptors may serve not only as potential therapeutic targets for treatment of depression and anxiety, but may also help enhance our understanding of the psychopathology of these two major psychiatric disorders.

Copyright 2009 Prous Science, S.A.U. or its licensors. All rights reserved.

PMID:
19771321
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Prous Science
    Loading ...
    Write to the Help Desk